FTFinancial Times·1dBusiness
score-0.40
Novartis Shares Decline as Muscular Disease Drug Trial Ends Without Success
Original
Novartis shares slide after drug for muscular disease fails trial
“Standard negative business reporting focusing on stock decline and R&D failure without catastrophizing or victim-blaming language.”